BR9808786A - Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro - Google Patents

Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro

Info

Publication number
BR9808786A
BR9808786A BR9808786-0A BR9808786A BR9808786A BR 9808786 A BR9808786 A BR 9808786A BR 9808786 A BR9808786 A BR 9808786A BR 9808786 A BR9808786 A BR 9808786A
Authority
BR
Brazil
Prior art keywords
treating
diseases associated
patient
processes
pharmaceutically acceptable
Prior art date
Application number
BR9808786-0A
Other languages
English (en)
Inventor
Stephen M Condon
Isabelle Morine
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of BR9808786A publication Critical patent/BR9808786A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSTO PEPTìDICO CìCLICO OU UM SEU SAL OU PRó-MEDICAMENTO FARMACEUTICAMENTE ACEITáVEIS, COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA TRATAR DOENçAS ASSOCIADAS COM A REGULAGEM DO CáLCIO EM UM PACIENTE E PARA TRATAR A OSTEOPENIA OU A OSTEOPOROSE EM UM MAMìFERO HOSPEDEIRO" Esta invenção é direcionada a análogos cíclicos e acíclicos do hPTH(1-34) e do hPTHrP(1-34), a composições farmacêuticas que compreenda estes compostos peptídicos e a um processo de tratar doenças associadas com a regulagem do cálcio no corpo.
BR9808786-0A 1997-05-14 1998-05-13 Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro BR9808786A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4647297P 1997-05-14 1997-05-14
PCT/US1998/009843 WO1998051324A1 (en) 1997-05-14 1998-05-13 Peptide parathyroid hormone analogs

Publications (1)

Publication Number Publication Date
BR9808786A true BR9808786A (pt) 2000-07-11

Family

ID=21943653

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808786-0A BR9808786A (pt) 1997-05-14 1998-05-13 Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro

Country Status (20)

Country Link
US (2) US6472505B1 (pt)
EP (1) EP0986395A4 (pt)
JP (1) JP2001517957A (pt)
KR (1) KR100351213B1 (pt)
CN (1) CN1261281A (pt)
AP (1) AP9901686A0 (pt)
AU (1) AU746461B2 (pt)
BG (1) BG103957A (pt)
BR (1) BR9808786A (pt)
CA (1) CA2290443A1 (pt)
EA (1) EA002819B1 (pt)
HU (1) HUP0003349A3 (pt)
IL (1) IL132901A0 (pt)
NO (1) NO995568L (pt)
OA (1) OA11216A (pt)
PL (1) PL336803A1 (pt)
SK (1) SK151599A3 (pt)
UA (1) UA62967C2 (pt)
WO (1) WO1998051324A1 (pt)
ZA (1) ZA984077B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1093458A4 (en) * 1998-04-15 2001-07-18 Aventis Pharm Prod Inc METHOD FOR THE PRODUCTION OF RESIN-TIED CYCLIC PEPTIDES
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US20040023882A1 (en) * 2002-05-16 2004-02-05 Peri Krishna G. PTH derivatives resistant to skin proteases
WO2004073587A2 (en) * 2003-02-19 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
WO2005007184A2 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
WO2007007325A2 (en) 2005-07-07 2007-01-18 Fulcrum Sp Ltd. Sp1 polypeptides, modified sp1 polypeptides and uses thereof
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
WO2008048784A1 (en) * 2006-10-13 2008-04-24 Eli Lilly And Company Pegylated pth as pth receptor modulators and uses thereof
CN102369015A (zh) 2009-02-02 2012-03-07 雷蒙特亚特特拉维夫大学有限公司 肽、包含该肽的药物组合物及其用途
EP2344179A1 (en) 2009-04-01 2011-07-20 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
CN102711789B (zh) 2009-07-29 2018-06-08 凯伊药品公司 用于降低甲状旁腺激素水平的治疗剂
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
EP2566500B1 (en) 2010-05-05 2017-04-12 Rappaport Family Institute for Research in the Medical Sciences Ccl1 for use in therapy
JP5941040B2 (ja) * 2010-05-13 2016-06-29 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン類似体およびその使用
EP2600885A2 (en) 2010-08-04 2013-06-12 Ramot at Tel Aviv University, Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN103534867B (zh) * 2011-06-17 2017-04-12 流体公司 含有磺酸根离子的离子液体
CN109116033A (zh) 2012-03-06 2019-01-01 塞莱克特生物疗法有限公司 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015145449A2 (en) 2014-03-27 2015-10-01 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
CA2977607A1 (en) 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
WO2017212476A1 (en) 2016-06-05 2017-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Novel molecules for the treatment of inflammation
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
BR112019003912A2 (pt) 2016-12-01 2019-05-28 Univ Ramot composição, método para criação de um hidrogel, matriz, hidrogel, método para indução da formação ou regeneração de um tecido neuronal, método para tratamento de uma lesão do nervo e método para prevenção ou tratamento de choque neurogênico após lesão do nervo
WO2018185768A1 (en) 2017-04-07 2018-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hair care compositions
US20200172604A1 (en) 2017-05-23 2020-06-04 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
WO2019016819A1 (en) 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. NANOPARTICLE COMPOSITIONS
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
EP3717032B1 (en) 2017-11-29 2023-02-15 Ramot at Tel-Aviv University Ltd. Methods of preventing or treating neurogenic shock
US20210214417A1 (en) 2018-07-11 2021-07-15 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
WO2021005599A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
WO2021156878A2 (en) 2020-02-09 2021-08-12 Nlc Pharma Ltd Rapid detection test for sars-cov-2
EP4114473A1 (en) 2020-03-05 2023-01-11 Ariel Scientific Innovations Ltd. Anti-hemorrhaging compositions
US20230127559A1 (en) 2020-03-16 2023-04-27 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
IL301503A (en) 2020-09-23 2023-05-01 Yeda res & development co ltd Methods and preparations for the treatment of the disease caused by the corona virus
IL301970A (en) 2020-10-07 2023-06-01 Protalix Ltd A long-acting DNase
WO2022097141A1 (en) 2020-11-03 2022-05-12 Protalix Ltd. Modified uricase and uses thereof
CA3208982A1 (en) 2021-02-18 2022-08-25 Ravid STRAUSSMAN Method of generating vaccines
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
WO2023031934A1 (en) 2021-09-02 2023-03-09 Yeda Research And Development Co. Ltd. Agents that target the glycine arginine-rich domain of nucleolin and uses thereof
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4427827A (en) 1982-10-20 1984-01-24 Usv Pharmaceutical Corporation Synthesis of hormone fragments
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
CA2087087C (en) 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
CA2098639A1 (en) 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE19508672A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE69629758T2 (de) 1995-06-07 2004-06-03 Compaq Computer Corp., Houston Verfahren und Vorrichtung für die Überwachung des Datenflusses in einem fehlertoleranten Multiprozessorsystem
US5717062A (en) * 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
GEP20033095B (en) * 1996-08-02 2003-10-27 Nat Res Council Canada Parathyroid Hormone Analogues for the Treatment of Osteoporosis

Also Published As

Publication number Publication date
EP0986395A4 (en) 2004-12-01
KR100351213B1 (ko) 2002-09-05
US20020132973A1 (en) 2002-09-19
IL132901A0 (en) 2001-03-19
OA11216A (en) 2003-07-10
NO995568D0 (no) 1999-11-12
EP0986395A1 (en) 2000-03-22
AU7386798A (en) 1998-12-08
SK151599A3 (en) 2000-09-12
EA002819B1 (ru) 2002-10-31
AP9901686A0 (en) 1999-12-31
AU746461B2 (en) 2002-05-02
HUP0003349A3 (en) 2001-12-28
HUP0003349A2 (hu) 2001-01-29
NO995568L (no) 1999-12-29
PL336803A1 (en) 2000-07-17
EA199901025A1 (ru) 2000-06-26
BG103957A (bg) 2000-04-28
US6472505B1 (en) 2002-10-29
UA62967C2 (en) 2004-01-15
CN1261281A (zh) 2000-07-26
CA2290443A1 (en) 1998-11-19
WO1998051324A1 (en) 1998-11-19
KR20010012568A (ko) 2001-02-15
JP2001517957A (ja) 2001-10-09
ZA984077B (en) 1998-11-24

Similar Documents

Publication Publication Date Title
BR9808786A (pt) Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
BR9206398A (pt) Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
IL78342A (en) Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
KR920703081A (ko) 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법
FR06C0032I2 (fr) Formulations proteiniques
BR9714200A (pt) Análogos de hormÈnio paratiróide
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
SE9702401D0 (sv) Pharmaceutical use
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
BR9710615A (pt) Uso de um agente na manufatura de um medicamento para o tratamento de doença metabólica óssea, e, agente de anti-absorção óssea.
BR9813208A (pt) Antagonista receptor de vitronectina
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
BR0012058A (pt) Combinação sinérgica: gabapentina e pregabalina
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
DE69915852D1 (de) Lhrh-analoga zur behandlung der osteoporose
ECSP982660A (es) USO DE ANALOGOS DEL PTHrP EN LA CICATRIZACION DE FRACTURAS

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B25D Requested change of name of applicant approved
B09B Patent application refused [chapter 9.2 patent gazette]